Differences in Lower Cranial Nerve Complications Predicted by the NTCP Model Between RTOG and Reduced-volume IMRT Planning in Radiotherapy for Nasopharyngeal Carcinoma

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35117184

Authors

Jianjun Qian

Yongqiang Yang

Pengfei Xing

Cuihong Wang

Ye Tian

Xueguan Lu

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to assess the differences in lower cranial nerve (LCN) complications predicted by the normal tissue complication probability (NTCP) model between Radiation Therapy Oncology Group (RTOG) and reduced-volume intensity-modulated radiotherapy (IMRT) planning for nasopharyngeal carcinoma (NPC) radiotherapy.

Methods: A total of fifty patients with NPC were divided into two groups according to T-stages of T1-2 and T3-4, and the LCNs of each patient were contoured on CT simulation images. The targets were contoured based on the RTOG 0225 clinical trial and a working committee for clinical stage NPC in China in 2010. The NTCP differences in LCNs between the two plans were calculated.

Results: The LCN volume of the 50 patients was 10.07 cc. The Dmax and Dmean of LCNs in RTOG plans were significantly larger than those in reduced-volume plans (7,453 7,401 cGy, 6,740 6,436 cGy, P=0.004, 0.000), and these values were lower in the T1-2 group than in the T3-4 group (7,390 7,464 cGy, 6,442 6,733 cGy, P=0.019, 0.000). NTCP in RTOG plans was significantly higher than that in reduced-volume plans (59.98% 51.62%, P=0.000), among which NTCP was significantly lower in the T1-2 group than in the T3-4 group (51.72% 59.88%, P=0.002). There were strong correlations of NTCP with Dmean and irradiation volume for more than 6,600 cGy (R=0.847, P=0.000; R=0.841, P=0.000).

Conclusions: the clinical T-stage, a high Dmean and a large irradiation volume are important factors in predicting LCN complications. Of the two most common IMRT guidance plans in China, the LCN NTCP based on the reduced-volume plan is significantly lower than that based on the RTOG plan.

Citing Articles

Precision Medicine for Nasopharyngeal Cancer-A Review of Current Prognostic Strategies.

Suryani L, Lee H, Teo W, Chin Z, Loh K, Tay J Cancers (Basel). 2024; 16(5).

PMID: 38473280 PMC: 10931317. DOI: 10.3390/cancers16050918.

References

Aggarwal P, Zaveri J, Goepfert R, Shi Q, Du X, Swartz M . Symptom Burden Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors. JAMA Otolaryngol Head Neck Surg. 2018; 144(11):1066-1076. PMC: 6248190. DOI: 10.1001/jamaoto.2018.1791. View

Mourad W, Young B, Young R, Blakaj D, Ohri N, Shourbaji R . Clinical validation and applications for CT-based atlas for contouring the lower cranial nerves for head and neck cancer radiation therapy. Oral Oncol. 2013; 49(9):956-963. DOI: 10.1016/j.oraloncology.2013.03.449. View

Zheng Y, Han F, Xiao W, Xiang Y, Lu L, Deng X . Analysis of late toxicity in nasopharyngeal carcinoma patients treated with intensity modulated radiation therapy. Radiat Oncol. 2015; 10:17. PMC: 4302701. DOI: 10.1186/s13014-014-0326-z. View

Hutcheson K, Yuk M, Hubbard R, Gunn G, Fuller C, Lai S . Delayed lower cranial neuropathy after oropharyngeal intensity-modulated radiotherapy: A cohort analysis and literature review. Head Neck. 2017; 39(8):1516-1523. PMC: 5511776. DOI: 10.1002/hed.24789. View

Janssen S, Glanzmann C, Yousefi B, Loewenich K, Huber G, Schmid S . Radiation-induced lower cranial nerve palsy in patients with head and neck carcinoma. Mol Clin Oncol. 2015; 3(4):811-816. PMC: 4487065. DOI: 10.3892/mco.2015.558. View

Webb S, Nahum A . A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. Phys Med Biol. 1993; 38(6):653-66. DOI: 10.1088/0031-9155/38/6/001. View

Wu S, Huang S, Zhou J, Sun J, Guo H, Li F . Dosimetric analysis of the brachial plexus among patients with breast cancer treated with post-mastectomy radiotherapy to the ipsilateral supraclavicular area: report of 3 cases of radiation-induced brachial plexus neuropathy. Radiat Oncol. 2014; 9:292. PMC: 4271326. DOI: 10.1186/s13014-014-0292-5. View

Lee N, Zhang Q, Pfister D, Kim J, Garden A, Mechalakos J . Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol. 2011; 13(2):172-80. PMC: 4985181. DOI: 10.1016/S1470-2045(11)70303-5. View

Lin S, Pan J, Han L, Zhang X, Liao X, Lu J . Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys. 2009; 75(4):1071-8. DOI: 10.1016/j.ijrobp.2008.12.015. View

10.

Au K, Ngan R, Ng A, Poon D, Ng W, Yuen K . Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 2018; 77:16-21. DOI: 10.1016/j.oraloncology.2017.12.004. View

11.

Burman C, Kutcher G, Emami B, Goitein M . Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991; 21(1):123-35. DOI: 10.1016/0360-3016(91)90172-z. View

12.

LYMAN J, Wolbarst A . Optimization of radiation therapy, III: A method of assessing complication probabilities from dose-volume histograms. Int J Radiat Oncol Biol Phys. 1987; 13(1):103-9. DOI: 10.1016/0360-3016(87)90266-5. View

13.

Huang T, Chien C, Tsai W, Liao K, Chou S, Lin H . Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy. Head Neck. 2015; 38 Suppl 1:E1026-32. DOI: 10.1002/hed.24150. View

14.

Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider J . Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21(1):109-22. DOI: 10.1016/0360-3016(91)90171-y. View

15.

Lee A, Law S, Ng S, Chan D, Poon Y, Foo W . Retrospective analysis of nasopharyngeal carcinoma treated during 1976-1985: late complications following megavoltage irradiation. Br J Radiol. 1992; 65(778):918-28. DOI: 10.1259/0007-1285-65-778-918. View

16.

Luk Y, Shum J, Sze H, Chan L, Ng W, Lee A . Predictive factors and radiological features of radiation-induced cranial nerve palsy in patients with nasopharyngeal carcinoma following radical radiotherapy. Oral Oncol. 2012; 49(1):49-54. DOI: 10.1016/j.oraloncology.2012.07.011. View

17.

Kong L, Lu J, Liss A, Hu C, Guo X, Wu Y . Radiation-induced cranial nerve palsy: a cross-sectional study of nasopharyngeal cancer patients after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 79(5):1421-7. DOI: 10.1016/j.ijrobp.2010.01.002. View

18.

Chow J, Cheung K, Au K, Zee B, Lee J, Ngan R . Radiation-induced hypoglossal nerve palsy after definitive radiotherapy for nasopharyngeal carcinoma: Clinical predictors and dose-toxicity relationship. Radiother Oncol. 2019; 138:93-98. DOI: 10.1016/j.radonc.2019.06.011. View

19.

Fu K, Pajak T, Trotti A, Jones C, Spencer S, Phillips T . A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG.... Int J Radiat Oncol Biol Phys. 2000; 48(1):7-16. DOI: 10.1016/s0360-3016(00)00663-5. View

20.

McDowell L, Rock K, Xu W, Chan B, Waldron J, Lu L . Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018; 102(2):340-352. DOI: 10.1016/j.ijrobp.2018.05.060. View